Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07325526 · ClinicalTrials.gov registry record · Phase 2
A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH)
A Phase 2 study of Liver Cirrhosis, sponsored by Boehringer Ingelheim.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 20
- Study locations
NCT07325526: Recruiting Phase 2 study of Liver Cirrhosis, sponsored by Boehringer Ingelheim.
NCT07325526 is a Phase 2 study of Liver Cirrhosis that is actively recruiting participants, run by Boehringer Ingelheim. The registered enrollment target is 30 participants, below the 1,003-participant average among 15 other Liver Cirrhosis trials with a reported enrollment target (97% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07325526, a Phase 2 study of Liver Cirrhosis, is actively recruiting participants, sponsored by Boehringer Ingelheim.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is open to adults with a type of confirmed liver condition called compensated cirrhosis due to Metabolic Dysfunction-Associated Steatohepatitis (MASH). The purpose of this study is to find out how well a study medicine called BI 3802876 is tolerated in people with this condition. The study looks at how different doses of BI 3802876 are handled by the body. BI 3802876 is being developed to improve liver health in people living with this liver condition. Participants are put in 3 different dose groups randomly, which means by chance. Participants within a group get BI 3802876 or placebo. Placebo looks like BI 3802876 but does not contain any medicine. Participants have more than twice the chance of receiving BI 3802876 than placebo. The study medicine is given as an infusion into a vein. Participants are in the study for about half a year. During this time, they visit the study site 12 times. At 2 visits, participants get the study medicine. Doctors collect information on any health problems and take blood samples to check how BI 3802876 is handled by the body. They compare results between the groups.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG BI 3802876
Study Locations (20)
California
- Southern California Research Center - Coronado
- Orange County Research Center - Lake Forest
- Pfleger Liver Institute - Los Angeles
- Catalina Research Institute, LLC - Montclair
- Velocity Clinical Research, San Diego - San Diego
Florida
- University of Miami - Miami
- Panax Clinical Research - Miami Lakes
Georgia
- Piedmont Healthcare-Atlanta - Atlanta
- Centricity Research Columbus Georgia Multispecialty - Columbus
Alabama
- University of Alabama at Birmingham - Birmingham
Colorado
- Peak Gastroenterology Associates - Colorado Springs
Iowa
- University of Iowa Hospitals and Clinics - Iowa City
Michigan
- Henry Ford Health System - Detroit
Minnesota
- Mayo Clinic, Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-02-27 |
| Est. Completion | 2027-03-29 |
| Phase | Phase 2 |
What NCT07325526 shows while recruiting
NCT07325526 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,003-participant average among 15 other Liver Cirrhosis trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Liver Cirrhosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07325526 names 20 study sites across 14 states, led by California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT07325526 about?
NCT07325526 is a clinical study titled "A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH)". This study is open to adults with a type of confirmed liver condition called compensated cirrhosis due to Metabolic Dysfunction-Associated Steatohepatitis (MASH). The purpose of this study is to find out how well a study medicine called BI 3802876 is tolerated in people with this condition. The stud...
What is the current status of trial NCT07325526?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2026-02-27. Estimated completion is 2027-03-29.
What conditions does trial NCT07325526 study?
This clinical trial studies the following conditions: Liver Cirrhosis.
What interventions are being tested in trial NCT07325526?
The interventions under investigation include: Placebo (DRUG), BI 3802876 (DRUG).
Who is sponsoring clinical trial NCT07325526?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07325526 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Liver Cirrhosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07325526's enrollment target sits among peer trials
30 15th of 15 the lowest of 15 other Liver Cirrhosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Liver Cirrhosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of IDN-6556 in Subjects With Liver Cirrhosis
COMPLETED · Phase 2
-
Satavaptan Dose-Ranging Study in Hyponatraemic Patients With Cirrhotic Ascites
COMPLETED · Phase 2
-
National Liver Cancer Screening Trial
RECRUITING · Phase 4
-
Multi-analyte Blood Test Clinical Trial
RECRUITING
-
HepHospital: A Pilot Trial of a Hepatology Home Hospital Intervention for Patients With Advanced Liver Disease
RECRUITING · NA
-
Value of [68Ga]Ga-PSMA-11 PET/MRI in the Assessment of Liver Cirrhosis
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI